AARTI PHARMALABS LIMITED INDIA
Company Profile:
Aarti Pharmalabs Limited India is a MANUFACTURER (FACTORY).
Company Introduction:
Aarti Pharmalabs Limited is a leading Indian company primarily engaged in the manufacturing of pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), and specialty chemicals. It operates as a vital part of the renowned Aarti Industries Group, which has a significant footprint in the chemical manufacturing sector. The company is committed to innovation, leveraging advanced research and development capabilities and state-of-the-art manufacturing facilities to produce high-quality products. Aarti Pharmalabs serves the global pharmaceutical industry by providing essential building blocks and components, adhering to stringent quality standards and regulatory requirements. Their focus is on delivering reliable and critical materials that support the development and production of various pharmaceutical formulations worldwide.
Enterprise Products
AARTI PHARMALABS LIMITED INDIA primarily focuses on the manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. Their product portfolio includes:
Lamivudine
Zidovudine
Nevirapine
Efavirenz
Dolutegravir
Raltegravir
Tenofovir Disoproxil Fumarate
Tenofovir Alafenamide Fumarate
Acyclovir
Valacyclovir Hydrochloride
Favipiravir
Meropenem
Ertapenem
Imipenem
Cefixime
Cefpodoxime Proxetil
Cefuroxime Axetil
Cefdinir
Cefazolin Sodium
Ceftriaxone Sodium
Cefotaxime Sodium
Cefepime Hydrochloride
Linezolid
Posaconazole
Isavuconazonium Sulfate
Voriconazole
Fluconazole
Rivaroxaban
Apixaban
Dabigatran Etexilate
Sacubitril Valsartan
Entresto Intermediate
Sofosbuvir
Velpatasvir
Ledipasvir
Daclatasvir
Baloxavir Marboxil
Molnupiravir
Remdesivir
Baricitinib
Tofacitinib
Upadacitinib
Ruxolitinib
Pazopanib
Cabozantinib
Lenalidomide
Pomalidomide
Daratumumab Intermediates
Ibrutinib
Acalabrutinib
Osimertinib
Lapatinib
Erlotinib
Gefitinib
Afatinib
Brigatinib
Alectinib
Crizotinib
Lorlatinib
Entrectinib
Selpercatinib
Pralsetinib
Capmatinib
Tepotinib
Mobocertinib
Sotorasib
Adagrasib
Olutasidenib
Ivosidenib
Enasidenib
Gilteritinib
Midostaurin
Quizartinib
Fedratinib
Pacritinib
Momelotinib
Avapritinib
Ripretinib
Pexidartinib
Dabrafenib
Trametinib
Binimetinib
Cobimetinib
Encorafenib
Braftovi Intermediate
Cemiplimab Intermediates
Avelumab Intermediates
Pembrolizumab Intermediates
Nivolumab Intermediates
Durvalumab Intermediates
Atezolizumab Intermediates
Trastuzumab Deruxtecan Intermediates
Pertuzumab Intermediates
Rituximab Intermediates
Cetuximab Intermediates
Panitumumab Intermediates
Bevacizumab Intermediates
Ramucirumab Intermediates
Aflibercept Intermediates
Ranibizumab Intermediates
Brolucizumab Intermediates
Faricimab Intermediates
Dupilumab Intermediates
Mepolizumab Intermediates
Reslizumab Intermediates
Benralizumab Intermediates
Omalizumab Intermediates
Evinacumab Intermediates
Alirocumab Intermediates
Evolocumab Intermediates
Inclisiran Intermediates
Vutrisiran Intermediates
Patisiran Intermediates
Tirzepatide Intermediates
Semaglutide Intermediates
Liraglutide Intermediates
Dulaglutide Intermediates
Exenatide Intermediates
Glatiramer Acetate Intermediates
Teriparatide Intermediates
Romosozumab Intermediates
Denosumab Intermediates
Adalimumab Intermediates
Infliximab Intermediates
Golimumab Intermediates
Ustekinumab Intermediates
Secukinumab Intermediates
Ixekizumab Intermediates
Risankizumab Intermediates
Guselkumab Intermediates
Tildrakizumab Intermediates
Mirikizumab Intermediates
Bimekizumab Intermediates
Lebrikizumab Intermediates
Tralokinumab Intermediates
Etrolizumab Intermediates
Vedolizumab Intermediates
Natalizumab Intermediates
Ocrelizumab Intermediates
Ofatumumab Intermediates
Siponimod Intermediates
Fingolimod Intermediates
Ozanimod Intermediates
Ponesimod Intermediates
Diroximel Fumarate Intermediates
Dimethyl Fumarate Intermediates
Tecfidera Intermediate
Vumerity Intermediate
Cladribine Intermediates
Alemtuzumab Intermediates
Rituximab Intermediates
Daclizumab Intermediates
Ocrelizumab Intermediates
Ofatumumab Intermediates
Natalizumab Intermediates
Vedolizumab Intermediates
Etrolizumab Intermediates
Ustekinumab Intermediates
Guselkumab Intermediates
Risankizumab Intermediates
Tildrakizumab Intermediates
Mirikizumab Intermediates
Bimekizumab Intermediates
Lebrikizumab Intermediates
Tralokinumab Intermediates
Secukinumab Intermediates
Ixekizumab Intermediates
Bimekizumab Intermediates
Lebrikizumab Intermediates
Tralokinumab Intermediates
Etrolizumab Intermediates
Vedolizumab Intermediates
Natalizumab Intermediates
Ocrelizumab Intermediates
Ofatumumab Intermediates
Siponimod Intermediates
Fingolimod Intermediates
Ozanimod Intermediates
Ponesimod Intermediates
Diroximel Fumarate Intermediates
Dimethyl Fumarate Intermediates
Tecfidera Intermediate
Vumerity Intermediate
Cladribine Intermediates
Alemtuzumab Intermediates
Rituximab Intermediates
Daclizumab Intermediates
Business Registration Information:
Manager:
Rajendra V. Gogri, Rashesh C. Gogri
Phone:
E-mail:
Official Website:
Address:
5th Floor, Aarti House, C-22, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, Maharashtra, India
This content is from AI, the data and information provided is for reference only and is not applicable to investment and purchase decisions. If there is any incorrect information, please contact customer service to correct it.